Literature DB >> 17873606

Variceal band ligation versus beta-blockers for primary prevention of variceal bleeding: a meta-analysis.

Dhiraj Tripathi1, Catriona Graham, Peter C Hayes.   

Abstract

BACKGROUND/AIMS: Variceal band ligation (VBL) can reduce the rate of the first variceal by 45-52% compared with beta-blockers (BBs). We performed an updated meta-analysis of nine randomized controlled trials published as full papers, comparing VBL with BB for primary prevention.
METHODS: Relative risk (RR) was computed using a random effects model. Sensitivity analysis was performed using a fixed effects model. Publication bias was also assessed using funnel plots and the rank correlation test.
RESULTS: In total, 734 patients were studied (356, VBL; 378, BB). The pooled RR favoured VBL for first variceal bleed [0.63; 95% confidence interval (CI), 0.43-0.92] with number needed to treat being 13 (95% CI, 7-33), and for adverse events resulting in treatment withdrawal (0.24; 95% CI, 0.12-0.47) with the corresponding number needed to treat being 10 (95% CI, 6-25). Banding-related bleeding occurred in six patients (fatal in two). No difference was seen in bleeding-related deaths (RR, 0.71; 95% CI, 0.38-1.32), or overall mortality (RR, 1.09; 95% CI, 0.86-1.38). No significant heterogeneity or publication bias was present, and outcomes remained robust after sensitivity analyses.
CONCLUSIONS: VBL was superior to BB in preventing the first variceal bleed, with fewer adverse events resulting in treatment discontinuation. Careful attention to technique and patient selection are important to minimize iatrogenic complications with VBL. VBL has a role in patients with poor drug compliance, or tolerance, and in those who bleed on BB therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873606     DOI: 10.1097/MEG.0b013e3282748f07

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

Authors:  Sonam Vadera; Charles Wei Kit Yong; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

Review 2.  Primary prophylaxis of bleeding from esophageal varices in cirrhosis.

Authors:  Carlo Merkel; Sara Montagnese; Piero Amodio
Journal:  J Clin Exp Hepatol       Date:  2013-09-07

3.  Endoscopic management of esophageal varices.

Authors:  Joaquin Poza Cordon; Consuelo Froilan Torres; Aurora Burgos García; Francisco Gea Rodriguez; Jose Manuel Suárez de Parga
Journal:  World J Gastrointest Endosc       Date:  2012-07-16

4.  Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT.

Authors:  Vipin Gupta; Ramakant Rawat; Anoop Saraya
Journal:  Hepatol Int       Date:  2016-09-13       Impact factor: 6.047

Review 5.  Carvedilol in the treatment of portal hypertension.

Authors:  Hamdan Al-Ghamdi
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

6.  Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension.

Authors:  Zeeshan Ahmad Wani; Sonmoon Mohapatra; Afaq Ahmad Khan; Ashutosh Mohapatra; Ghulam Nabi Yatoo
Journal:  World J Hepatol       Date:  2017-02-18

Review 7.  Beta-blockers in cirrhosis: Evidence-based indications and limitations.

Authors:  Susana G Rodrigues; Yuly P Mendoza; Jaime Bosch
Journal:  JHEP Rep       Date:  2019-12-20

8.  After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis?

Authors:  Zeeshan A Wani; Riyaz A Baht; Ajeet S Bhadoria; Rakhi Maiwall; Yamin Majeed; Afaq A Khan; Showkat A Zargar; Mohd A Shah; Kaiser M Khan
Journal:  Saudi J Gastroenterol       Date:  2015 Sep-Oct       Impact factor: 2.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.